Lento Bio

Lento Bio is a startup based in the United States. Its most recent tracked round is Seed. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Lento Bio is a biotechnology company developing small-molecule topical eye-drop therapeutics that target and reverse age-related molecular damage in the crystalline lens to restore near vision (presbyopia) and potentially prevent cataracts. Their pipeline includes LB-01 and LB-02 for presbyopia and a cataract-prevention indication, in discovery and IND-enabling stages.